Lineage Cell Therapeutics, Inc. · AMEX:LCTX
Lineage Cell Therapeutics — Biotime — Investor Presentation (April 2019)
37 slides from Lineage Cell Therapeutics's investor presentation, Apr 23, 2019
Slide 1: Corporate Presentation
Exhibit 99.1 i wei = BIOTIME NYSE American: BTX x >» Corporate Presentation April 23, 2019
Slide 2: Forward Looking Statements
Forward Looking Statements This presentation is for informational purposes only ands not an offer to sell or a solicitation of an offer to buy any securities of BioTime, Inc. (“BioTime” or the “Company”). This presentation includes certain information obtained from trade and statistical services, th
Slide 3: BioTime Overview
BioTime Overview > BioTime is a leading cell therapy company >» Expertise is differentiating pluripotent cells into specific cell types for use as whole-cell transplants > Three clinical-stage programs: = Phase 1/2 in dry macular degeneration (dry-AMD) = Phase 1/2 in spinal cord injury = Phase 1 in
Slide 4: Cell Therapy Platform Technology
Y Cell Therapy Platform Technology
Slide 5: Cell Therapy Platform Technology
Cell Therapy Platform Technology > BioTime’s cell therapy platform starts with normal, pluripotent oe human cells, which avoids risks from genetic modifications. a Vascular Endothelium/ Vascular Smooth Muscle : > The cells have high proliferative Lindh a capacity and could produce Cells material to
Slide 6: Cell Therapy Platform Technology
Cell Therapy Platform Technology > BioTime’s cell therapy platform starts with normal, pluripotent oe human cells, which avoids risks from genetic modifications. a Yuet Endo fascular Smooth Muscle : > The cells have high proliferative Lindh a capacity and could produce Cells material to treat even t
Slide 7: In-House Process Development and GMP Production Capabilities
In-House Process Development and GMP Production Capabilities > Stem cell banking and handling > Process development from pluripotent stem cells to differentiated cell types (i.e. retina cells, glial cells, etc.) > Manufacturing of clinical material > Scale-up production in bioreactors > Clean rooms
Slide 8: Clinical-Stage Pipeline
Clinical-Stage Pipeline Partnerships & Cell Therapy Phase I Phase II External Funding OpRegen® P<y apwinanw Dry Form Adult Macular Degeneration eS a3 lez novation with GA (Dry AMD) oPci —— cIRM Spinal Cord Injury vac2 —" oe fesearcn Non-Small Cell Lung Cancer “bye UK Medical Aesthetics Clinical Tria
Slide 9: OpRegen®
'Z OpRegen® Retinal Pigment Epithelium Transplant Therapy for Dry-AMD
Slide 10: Age-related Macular Degeneration (AMD)
Age-related Macular Degeneration (AMD} > AMD is a common eye disorder causing impaired central vision > Leading cause of blindness in those over 60 years > Retinal damage occurs from the build-up of acellular debris called drusen. > Retinal pigment epithelial (RPE) cells help clear the waste materia
Slide 11: OpRegen® - Treating the Pathology of AMD
OpRegen® - Treating the Pathology of AMD > OpRegen is a suspension of RPE cells injected into the sub-retinal space. > Potential Benefits of replacing RPE cells: = RPE organization = Drusen reduction = Photoreceptor recovery = Preserved or improved sight — aN AY recovery VAG Choroid ma BIOTIME cE
Slide 12: Engraftment and Survival of Human RPE Cells
Engraftment and Survival of Human RPE Cells > OpRegen cells counter-stained with DAPI (red line) > OpRegen cells form a sustained monolayer in multiple species RCS Rat NOD-SCID Mouse Pig 19 weeks post transplantation 2 months post transplantation 2 months post transplantation ne ae anti-GFP anti-hum
Slide 13: Improved Visual Acuity in RCS Rat Model
Improved Visual Acuity in RCS Rat Model Dose-dependent rescue of vision observed with optokinetic tracking 0.6 Untreated/Control Untreated-os G os “ > 7 x masse 4 g 04 - T = 25K Cells 3 g - | 100K cells = 03 > R = 200K Cells g = z 02 OpRegen-treated inred B o1 0 60 100 150 200 Age (Days) = BIOTIME w
Slide 14: OpRegen® - Phase 1/2a Trial Design
OpRegen® - Phase 1/2a Trial Design PART 1 (legally blind) Cohort 1 e 3 Patients BCVA 20/200 or less 50,000 cells Cohort 2 @ 3 Patients BCVA 20/200 or less 200,000icalls Cohort 3 e 6 Patients 100,000 cells BCVA 20/200 or less PART 2 (impaired vision) 100,000 cells Cohort 4 12 Patients BCVA > 20/64 an
Slide 15: Phase 1/2a Patient Data: Cell Engraftment
Phase 1/2a Patient Data: Cell Engraftme Stable engraftment of OpRegen RPE cells in a human subject Region of GA, identifiable as lighter circular area Baseline - on retina In areas of administration, pigmentation is consistent with normal retinal appearance, suggesting successful engraftment of cell
Slide 16: Phase 1/2a Patient Data: Evidence of Drusen Reduction
Phase 1/2a Patient Data: Evidence of Drusen Reduction > Drusen build-up is observed at baseline (irregular white line) > Reduction or change of drusen observed through month 9 in some patients Untreated = BIOTIME ‘
Slide 17: Phase 1/2a Highlights
Phase 1/2a Highlights > OpRegen® has been well-tolerated, shows signs of structural improvementin the retina, and decreases in drusen density in some patients > Improvements or possible restorations of the ellipsoid zone and RPE layers have persisted. = The photoreceptor layer and ellipsoid zone ass
Slide 18: Subretinal Delivery Challenges
Subretinal Delivery Challenges > Standard transvitreal techniques used to access the subretinal space involve vitreous removal (vitrectomy) and incision of the retina (retinotomy). > Vitrectomy complications can include retinal tear/detachment and cataract formation. > Transvitreal delivery complica
Slide 19: Subretinal Delivery Solution
Subretinal Delivery Solution > BioTime has partnered with Orbit Biomedical to use their vitrectomy-free subretinal injection device. > The device allows for access to the subretinal space via a suprachoroidal approach with a flexible cannula. > A microneedle inside the cannula is advanced into the s
Slide 20: Significant Market Opportunity
Significant Market Opportunity > AMD afflicts ~11 million people in the United States! > ~$6B in approved Wet-AMD therapies?: Lucentis® and Eylea® >» Currently, no approved therapies available for Dry-AMD 10% Wet AMD? Sources: (1) Pennington and DeAngelis, Eye and Vision, 2016 3:34; (2) IM Seddon, E
Slide 21: OPC1
'Z OPC1 Oligodendrocyte Precursor Cell Therapy for Spinal Cord Injury
Slide 22: Lucas Linder was paralyzed from the neck down following a car accident
Lucas Linder was paralyzed from the neck down following a car accident. The next year, he threw out the first pitch at a Major League Baseball game. = BIOTIME
Slide 23: OPC1 Overview
Jt OPC1 Overview > OPC1 utilizes non-patient specific oligodendrocyte progenitor cells (OPCs) > OPCs are naturally-occurring precursors to the cells which provide electrical insulation for nerve axons in the form of a myelin sheath > OPC1 has RMAT and Orphan Drug Designations from the FDA > OPC1 has
Slide 24: OPC1 Potential Mechanisms of Action
OPC1 Potential Mechanisms of Action Myelination of axons Secretion of neurotrophic factors shiverer mouse shi mouse + OPC1 Control Media OPC1CM f 3) <6 Control oPci + Rag2/-yc/-/shi mouse + OPC1 = BIOTIME
Slide 25: OPC1 Development in Spinal Cord Injury
OPC1 Developmentin Spinal Cord Injury 28 Animal Studies Phase 1 Thoracic Study = Survives in the Spinal Cord = 5 subjects administered 2M cells = Greatest Activity in Subacute Injury = Long-term follow up has shown no = Improves Locomotor Activity evidence of adverse changes in any = Reduces Parench
Slide 26: Clinical Data from OPC1 Phase 1/2a Study
Clinical Data from OPC1 Phase 1/2a Stud Cell Engraftment Improved Motor Function (cohorts 2-4 (95%) at 12 months, n=18; (cohort 2-4 at 12 months, n=18) and cohort 5 (100%) at 6 months, n=4) At Least One 95% Level (94%) Z Two or More Successful WY J revels (33%) Engraftment GY J Safety To date, no se
Slide 27: OPC1 in Spinal Cord Injury (SCI)
OPC1 in Spinal Cord Injury (SCI) » SCI can create a significant burden for patients and Spinal cord caregivers* posted = 60% of cases result in some degree of tetraplegia and Cervical nerves. . i Head and ni 40% with some degree of paraplegia "Dlecheaoe = 67% of patients are unemployed 10 years post
Slide 28: VAC2
'Z VAC2 Dendritic Cell Transplant Therapy for Cancer (NSCLC)
Slide 29: VAC2 Immunotherapy Program
VAC2 Immunotherapy Program > VAC2 uses allogeneic ("off the shelf”) dendritic cells to stimulate an immune response to an antigen present in >85% of all cancers > The LAMP signal sequence heightens the immune response through stimulation of both CD8+ cytotoxic and CD4+ helper T cell responses > Opti
Slide 30: Cancer Research UK Partnership
Cancer Research UK Partnership CANCER RESEARCH ate Ui > CRUK Responsibilities: Funding and Management - GMP Manufacture of VAC2 Clinical Material . Prepare and File Regulatory Dossier - Conduct 24-patient Phase 1/2a trial in Patients with Advanced and Resected Non-small Cell Lung Cancer (NSCLC) >4 p
Slide 31: VAC2 Platform has Potential Broad Application
VAC2 Platform has Potential Broad Applica Approach: Monotherapy in MRD Setting with High Risk of Relapse Combination Therapy New or Additional Antigens ma BIOTIME ~ la Vv Rationale: Stimulate T cell response to eliminate residual cancer cells after debulking chemotherapy, surgery, radiotherapy Stimu
Slide 32: Renevia®
Renevia® Cell support and delivery platform
Slide 33: Renevia®
Renevia® > A proprietary matrix designed to support transplanted cells = Intended to mimic the extracellular matrix = Localizes transplanted cells at an injection site = Explored clinically as a volumizer to augment fat transfer procedures v 50-patient, HIV-Associated Lipoatrophy Study = Increase in
Slide 34: Financial Overview
Financial Overview > Cash and cash equivalents and marketable securities (as of 12/31/2018) = $30.7 million > Value of Equity Holdings in OncoCyte Corporation (OCX) (based on closing stock price on 4/18/2019) = $60.9 million > Convertible promissory note due from Juvenescence (as of 12/31/2018) = ~§
Slide 35: Investment Highlights
Investment Highlights > BioTime:a leading cell therapy company > Innovative and diversified pipeline with three clinical-stage programs, each transplanting whole differentiated cells for unmet medical needs: Dry AMD with GA Spinal Cord Injury Non Small Cell Lung Cancer > Recent Significant Events: B
Slide 36: Select Upcoming Milestones
Select Upcoming Milestones > Present updated results from the ongoing Phase I/Ila clinical study of OpRegenat 2019 ARVO Annual Meeting. > Initiate dosing with the Orbit injection device and a new thaw and inject formulation in ongoing Phase I/Ila clinical study of OpRegen, anticipated Q2 2019. > Int
Slide 37: NYSE American: BTX
NYSE American: BTX